Sunshine Biopharma Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-12-31 was $724.50K, a 55.23% decline year-over-year.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-06-30 was $1.84M.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-03-31 was $355.30K, a 689.55% increase year-over-year.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $2.92M, a 17.96% decline from fiscal 2024.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $3.56M, a 101522.27% increase from fiscal 2023.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $3.50K, a 99.97% decline from fiscal 2022.
- Sunshine Biopharma Inc. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $13.19M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $724.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $2.92M 10-K · filed 2026-04-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.81M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $1.84M 10-Q · filed 2025-08-12 | $5.71M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-03-31 | $355.30K 10-Q · filed 2026-05-13 | $3.87M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-03 | $3.56M 10-K · filed 2026-04-03 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-13 | $1.94M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $47.35K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $45.00K 10-Q · filed 2025-05-15 | $48.50K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.35K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $3.50K 10-K · filed 2025-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-05 | |
| 2023-06-30 | $1.16K 10-Q/A · filed 2024-08-20 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $13.19M 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $12.37M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $822.40K 10-Q · filed 2023-05-10 | |
| 2020-12-31 | $2.52M 10-K · filed 2021-03-30 | |
| 2019-12-31 | $566.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $717.73K 10-K · filed 2021-03-30 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.45M derived: sum of 4 quarters · filed 2020-05-01 |
| 2019-06-30 | $103.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-15 | $1.65M derived: sum of 4 quarters · filed 2020-05-01 |
| 2019-03-31 | $47.31K 10-Q · filed 2019-05-20 | $1.54M derived: sum of 4 quarters · filed 2020-05-01 |
| 2018-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-01 | $1.59M 10-K · filed 2020-05-01 |
| 2018-09-30 | $194.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $290.04K derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-15 | $95.05K derived: sum of 4 quarters · filed 2019-08-15 |
| 2018-03-31 | $95.05K 10-Q · filed 2019-05-20 | $95.05K derived: sum of 4 quarters · filed 2019-05-20 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-12 | $128.45K 10-K · filed 2019-04-12 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-16 | $439.15K derived: sum of 4 quarters · filed 2018-11-16 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-17 | $2.83M derived: sum of 4 quarters · filed 2018-08-17 |
| 2017-03-31 | $128.45K 10-Q · filed 2018-05-22 | $2.83M derived: sum of 4 quarters · filed 2018-05-22 |
| 2016-12-31 | $310.70K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $3.08M 10-K · filed 2018-04-02 |
| 2016-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-15 | $3.17M derived: sum of 4 quarters · filed 2017-11-15 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $778.56K derived: sum of 4 quarters · filed 2017-08-11 |
| 2016-03-31 | $377.81K 10-Q · filed 2017-05-12 | $1.02M derived: sum of 4 quarters · filed 2017-05-12 |
| 2015-12-31 | $400.75K derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-17 | $977.49K 10-K · filed 2017-04-17 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $644.74K derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $243.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-16 | $51.34K derived: sum of 4 quarters · filed 2016-08-16 |
| 2015-03-31 | $333.14K 10-Q · filed 2016-05-09 | -$111.86K derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-25 | $68.00K 10-K · filed 2016-03-25 |
| 2014-09-30 | -$593.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 4 quarters · filed 2015-11-04 |
| 2014-06-30 | $80.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $593.40K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | $513.00K 10-Q · filed 2015-05-07 | $449.69K derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $513.00K 10-K · filed 2015-03-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $513.00K derived: sum of 4 quarters · filed 2014-11-12 |
| 2013-06-30 | -$63.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $513.00K derived: sum of 4 quarters · filed 2014-08-12 |
| 2013-03-31 | $576.31K 10-Q · filed 2014-05-09 | $576.31K derived: sum of 4 quarters · filed 2014-05-09 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-19 | $0.00 10-K · filed 2014-03-19 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $0.00 derived: sum of 4 quarters · filed 2012-11-08 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $0.00 derived: sum of 4 quarters · filed 2012-11-08 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-08 | $0.00 derived: sum of 4 quarters · filed 2012-11-08 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-19 | $0.00 10-K · filed 2012-03-19 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $0.00 derived: sum of 4 quarters · filed 2012-11-08 |
| 2011-06-30 | $0.00 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $0.00 10-Q · filed 2012-05-08 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-19 | $0.00 10-K · filed 2012-03-19 |
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | |
| 2010-03-31 | $0.00 10-Q · filed 2011-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |